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Human immunodeficiency virus type 1 (HIV-1) is a major health threat in South Africa. Studies 
have shown that HIV affects the central nervous system (CNS), and can initiate a progressive 
neurodegenerative process culminating in HIV associated dementia. Tat protein and gp120 are 
two viral proteins that have been linked to the neurotoxic effects of HIV. The present study used 
an animal model to study the effects of tat protein on the brain. The study also investigated the 
ability of picolinic acid to block the damaging effects of Tat protein. 
Sprague-Dawley rats were divided into four groups. The control group received a bilateral 
injection of saline (100µl), and the experimental group received a bilateral injection of tat protein 
(5µg/100µl) into the hippocampus. The other two groups of rats were treated similarly, but also 
received picolinic acid at a concentration of 3.36mg/3ml, injected intraperitoneally (i.p) before 
the intrahippocampal injections. Two tests were performed to assess the cognitive behaviour of 
all the animals, namely the light/dark box and Morris water maze. After the behavioural tests, the 
brains of animals were collected for evaluating the activity of the enzyme caspase 3 by various 
means. Some brains were used to determine caspase 3 mRNA transcriptions by polymerase chain 
reaction; others were used to measure the expression of caspase 3 protein by Western blotting 
techniques, while the rest of the brains were used for flow cytometry analysis where a caspase 3 
specific staining kit was used. 
Our behavioural results indicated that tat protein caused impairment in learning and memory in 
the experimental group, when compared to controls. The group that received both tat protein and 
picolinic acid showed a significant improvement in learning and memory in Morris water maze 
test, in comparison to the tat protein treated group. 
Our gene expression data showed a significant up regulation of caspase 3 gene in the tat protein 
treated group, compared to controls. This result was supported by the Western blot data that 
showed significantly increased caspase 3 protein expression in the tat protein treated group. 
While these increases in caspase 3 expression strongly point to an apoptotic mode of cell death in 
the hippocampus of animals that were treated with tat protein, our flow cytometry results were 
less convincing with marginal levels of caspase 3 staining being observed. Both increases in 
gene and protein expression were inhibited in animals that were pretreated with picolinic acid.   
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Our data led us to conclude that tat protein can cause cognitive abnormalities through toxic 
sequelae that may include apoptosis. It is therefore likely that this viral protein may be one of the 
etiological factors of HIV associated neurocognitive impairment. Our results further suggest that 

































1. Scope of the HIV problem 
HIV and AIDS (acquired immunodeficiency syndrome) has become a serious problem in South 
Africa and worldwide (UNAIDS, 2011). Recently the UNAIDS reported that approximately 34 
million people are living with HIV, and about 30 million people have died of AIDS-related 
causes since the beginning of the epidemic (Table 1, UNAIDS, 2011). Global statistics suggest 
that 3.4 million children have been diagnosed with HIV in 2010, of which 390 000 were new 
infections.  
 
Table 1: HIV Prevalence and Incidence by Region 
Region Total no. (%) living 
with HIV at the end 
of 2010 
Newly infected in 
2010 
Adult prevalence % 
in 2010  
Global total 34 million (100) 2.7 million 0.8 
Sub-Saharan Africa 22.9 million (67) 1.9 million 5.0 
South/South-East 
Asia 
4.0 million (12) 270 000 0.3 
Eastern Europe/ 
Central Asia 
1.5 million (4) 160 000 0.9 
Latin America 1.5 million (4) 100 000 0.4 
North America 1.3 million (4) 58 000 0.6 
Western/Central 
Europe 
840 000 (2) 30000 0.2 
East Asia 790 000 (2) 88 000 0.1 
Middle East/ North 
Africa 
470 000 (1) 59 000 0.2 
Caribbean 200 000 (0.6) 12 000 0.9 
Oceania 54 000 (0.2) 3 300 0.3 
UNAIDS Report on the Global HIV/AIDS Epidemic 2011, Kaiser Family Foundation. 
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The number of AIDS orphans were estimated to be approximately 16.6 million i.e. children who 
have lost one or both parents due to HIV, with most of them living in sub-Saharan Africa (89%) 
(UNAIDS, 2011; UNAIDS Kaiser Family Foundation, 2011). While 1.8 million AIDS-related 
deaths have been documented for 2010, the overall number is on a declining trajectory, with a 
decreased of 21% reported since 2005. This reduction is mainly attributed to the roll-out of 
antiretroviral treatment (ART).  
Sub-Saharan Africa is the region that has the highest prevalence rate of people living with HIV. 
In this region there are 9 countries where more than 10% of adults are estimated to be HIV-
positive; with South Africa having the highest score (UNAIDS Kaiser Family Foundation 
Report, 2011).  
Table 2: HIV prevalence estimates and the number of people living with HIV, 2002–2011  
Year  
Population 15-49 years infected with HIV Incident 
Adult  
15-49 years 





% of the 
population  




17.7  16.2  9.6  1.59  4.37  
2003  
18.0  16.2  9.7  1.58  4.49  
2004  
18.1  16.2  9.8  1.63  4.59  
2005  
18.3  16.2  9.9  1.73  4.69  
2006  
18.9  16.6  10.2  2.11  4.87  
2007  
18.9  16.5  10.2  1.54  4.95  
2008  
18.9  16.4  10.3  1.43  5.02  
2009  
19.1  16.4  10.4  1.45  5.13  
2010  
19.3  16.5  10.5  1.43  5.26  
2011  
19.4  16.6  10.6  1.38  5.38  




According to Statistics South Africa (2011) there are more than 50 million people in the country. 
Of this 5.38 million people are HIV positive, the majority being between the ages of 15 and 49 
(Table 2). The total prevalence of HIV infection is approximated to be 10.6% (Table 2, Mid-year 
population estimates, 2011). 
The South African National AIDS Council (2011) investigated the characteristics of the new 
cases that present with HIV infection and found those men who have sex with men (MSM), sex 
workers (SW) and their clients, and injection drug users (IDU) to be the most prominent (Table 
3). Worryingly, it is estimated that half of homosexual men living in Johannesburg, are HIV 
positive. These findings are supported by studies of the South African Centre for 
Epidemiological Modeling and Analysis (SACEMA) that indicated 9.2% of new HIV infections 
to be associated with MSM. SACEMA also estimated that 19.8% of all new HIV infections are 
interrelated with sex work. Other reports from the South African National AIDS Council (2011) 
and the Medical Research Council of South Africa (Parry, 2008) showed that 86% of South 
Africans who inject illicit drugs, share injection equipment. In addition, these persons also 
practice unsafe sex. The scope and enormity of the HIV/AIDS problem is therefore obvious and 
this justifies its present top position on the South African health and research agenda. 
 
Table 3. Percent of new infections attributed to sex workers (SW), injection drug users 
(IDU) and homosexual men (MSM) 
 
 
Percent of new HIV        
infections, group only  
 
 
Percent of new infections, group    
and their partners/clients  
SW   5.5%   19.8%  
IDU   1.1%   1.3%  
MSM   7.9%   9.2%  
Total   14.5%   30.3 








2. Human immunodeficiency virus (HIV) 
2.1. The virus structure  
Human immunodeficiency virus (HIV) belongs to the retrovirus family. The virus has an outer 
envelope (outer membrane), embedding an RNA genome. This RNA genome is surrounded by a 
capsid, forming a nucleus that also accommodates viral proteins vital for its replication. Between 
the envelope and capsid (cytosol) core and matrix proteins are found (Figure 1; Mattson et al., 
2005; Kaul et al., 2001). The HIV genome has three main regions namely env, pol and gag 
(Figure 1). They code for a range of viral proteins. For example, env gene encodes for the 
glycoprotein gp160 which is cleaved to form two important envelope proteins, gp120 and gp41 
(Figure 1; Nath and Geiger, 1998; van de Bovenkamp et al., 2002; Mattson et al., 2005). Gp120 
is responsible for the spikes that can be seen on the surface of the virus, and is the protein that 
interacts with CD4 and CCR5 binding proteins on T-helper cells (Kaul and Lipton, 1999; 
Kashou and Agarwal, 2011). Gp41 is a trans-membrane glycoprotein that anchors these spikes in 
the envelope (Figure 1), and facilitates fusion and internalisation of the virus into the host cell 
(El-Kharroubi et al., 1998). Pol gene codes for the enzyme reverse transcriptase that converts 
viral RNA to DNA (Mattson et al., 2005), as well as the protease and intergrase enzymes that are 
important in viral replication. Group specific antigen (Gag) proteins are integral to the capsid, 
matrix and nucleocapsid. There are also at least six regulatory proteins namely tat, rev, nef, vif, 
vpu and vpr (Mattson et al., 2005). Tat and rev are nuclear proteins, while nef may be found in 
both the nucleus and the cytoplasm of the host cell. Usually tat is actively released in the 
extracellular environment, where it may affect adjacent cells (van de Bovenkamp et al., 2002; 




Figure 1: The structure of HIV and proteins that are involved in replication (El-Kharroubi et al., 
1998) 
2.2. HIV replication 
HIV-1 mainly targets cells of the immune system. HIV-1-infected T-lymphocytes have been 
detected within 4-6 weeks after HIV-1 inoculation (Ghafouri et al., 2006). However, post-
mortem studies have indicated the presence of HIV in tissue of the central nervous system (CNS) 
as well (Kaul et al., 2005).  
 
Cells that become infected with HIV possess receptors that facilitate binding of HIV-1 to the cell 
membrane (Ghafouri et al., 2006; Wayengera, 2010). Chemokine receptors, such as CXCR4, are 
important for HIV-1 entry into the lymphocytes, while CCR5 performs a similar function for 
monocytes, macrophages and microglia. Entry of the virus into the cell is followed by a series of 
steps that include reverse transcription of viral RNA, nuclear entry of double-stranded viral 
DNA, viral integration into host genome, viral genomic replication, viral packaging and finally 




Figure 2: An illustration of the HIV replication process (Wayengera, 2010) 
 
 




2.3. HIV and hippocampus dysfunction 
HIV crosses the blood brain barrier (BBB) soon after the person is infected. Previous studies 
revealed that brain structures such as the basal ganglia, deep white matter, subcortical and fronto-
striatal areas of the brain are affected by HIV (Castelo et al., 2007). Neuroimaging data has 
shown a decrease or volume loss in the cortical or subcortical region, and hypertrophy is 
apparent in the basal ganglia, especially the putamen (Castelo et al., 2007; Cohen et al., 2010).  
The hippocampus is known for its important role in learning and memory, and also spatial 
navigation (Castelo et al., 2007; Venkatesan et al., 2007). Loss of memory, poor attention and 
visuospatial functioning, have been observed in patients infected with HIV (Cohen et al., 2010). 
These observations strongly implicated the hippocampus in HIV associated neurocognitive 
impairment (Antinori et al., 2007).   
2.4. HIV – associated neurocognitive impairments 
The term HIV dementia was introduced by Navia and Price (1987) to describe the mild memory 
loss, motor slowing and incapacitating cognitive collapse that they observed in HIV patients. 
More recently, the classification of these symptoms was revised and the disorder is now referred 
to as HIV associated neurocognitive disturbance (HAND), consisting of three syndromes: 
asymptomatic neurocognitive impairment (ANI); mild neurocognitive disorder (MND); and HIV 
associated dementia (HAD) (Antinori et al., 2007). ANI doesn’t interfere with daily work and 
doesn’t meet any requirement for dementia. MND produces at least mild interference which may 
result in unwanted disruptions in normal working, homemaking, or social functioning (Antinori 
et al., 2007). HAD on the other hand, is characterised by marked interference in day-to-day 
functioning. The extent of this disorder includes the loss of learning and memory, recalling and 
motor deficits.  
 
3. Treatment of HIV associated dementia (HAD) 
The treatment of HAD is complicated by the presence of the blood brain barrier, that limits the 
penetration of drugs into the CNS (Saksena and Smith, 2005; Li et al., 2009; Joska et al., 2011).  
Although the administration of highly active anti-retroviral therapy (HAART) has improved the 
quality of life of many HIV patients, its overall efficacy for neuroAIDS remains unsatisfactory 
(Joska et al., 2011). Studies have shown that in the pre-HAART era  dramatic  volumetric brain 
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abnormalities were seen in people  infected with HIV (Cohen et al., 2007; Castole et al., 2010). 
There is some indication that reduced subcortical volumes and metabolite abnormalities can be 
found in HIV-infected patients on HAART, and patient on HAART are still experiencing cortical 
atrophy problem (Cohen et al., 2007). Questions as to why HAD continues to prevail in the era 
of HAART, despite considerable success of HAART regimens and protease inhibitors in 
particular, are continuously being asked (Saksena and Smith, 2005; Joska et al., 2011).  
In general, current treatment strategies are based on combination therapy that include 
nucleotide/nucleoside reverse transcriptase inhibitors (eg. lamivudine and stavudine), and non-
nucleotide/nucleoside reverse transcriptase inhibitors (eg. nevirapine and efavirenz) (Saksena 
and Smith, 2005; Joska et al., 2011). These drugs usually act by binding directly to the active site 
of the reverse transcriptase enzyme, and so prevent the replication of HIV (Saksena and Smith, 
2005). 
HIV proteases are the enzymes that cleave protein molecules into smaller fragments, and at the 
same time they are responsible for both viral replication within the cell, and release of mature 
viral particles from an infected cell (De Clercq, 2004; Gills et al., 2007). There are now protease 
inhibitors for HIV (saquinavir, ritonavir, indinavir, nelfinavir, amprenavir), and these inhibitors 
are more effective if they are given with food, and also in combination with other drugs (De 
Clercq, 2004; Gills et al., 2007).  
Other pharmacological approaches have also been investigated in the search for better 
management of HAD. For instance, NMDA receptor blockers, chemokines, chemokine-receptor 
and cytokine-receptor antagonists, p38 MAPK inhibitors, caspase inhibitors and antioxidants 
(free-radical scavengers or other inhibitors of excessive nitric oxide or reactive oxygen species) 
have been examined as possible adjunct treatments for the HIV syndrome (Kaul et al., 2001). 
Similarly, β-chemokines that act as antagonists of CXCR4 and CCR5 have been proposed to be 
useful to treat HIV, since it has been shown to prevent gp120-induced neuronal apoptosis in in 
vitro studies (Kaul et al., 1999; Kaul et al., 2001).  
There are 3 other drugs that are currently under study for use in patients that live with AIDS 
dementia. They are nimodipine (an L-type calcium-channel antagonist), and memantine and 
nitroglycerin (both NMDA-receptor antagonists) (Lipton and Gendelman, 1995; Parsons et al., 
2007). These novel approaches are mostly in the experimental stage and their true benefit for 
HAD remains to be established. Furthermore, the blood brain barrier impedes entry of the drugs 
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into the brain, thereby hindering the obtaining of effective doses to combat HIV. It is therefore 
imperative that the search for better therapeutic interventions continues.  
Activation of the kynurenine pathway in the brain has been associated with inflammatory 
neurological diseases (Heyes et al., 1992). Basically this biochemical pathway entails the 
breakdown of L-tryptophan to quinolinic acid, and high levels of quinolinic acid have been 
found in the cerebrospinal fluid or post-mortem brain tissue of HIV-infected individuals (Heyes 
et al., 1992, Sanni et al., 1998; Guillemin et al., 2005). Picolinic acid is another pyridine 
compound that is produced along with quinolinic acid during L-tryptophan catabolism (Grant et 
al., 2009). While quinolinic acid is noted for its harmful effects to neurons, picolinic acid on the 
other hand has been reported to have more of a neuroprotective role (Grant et al., 2009). 
 
4. HIV-1 neurophathogenesis in the CNS 
The blood–brain barrier (BBB) (Figure 4) is composed of a tightly bound layer of capillary 
endothelial cells that separates the CNS from the periphery (Gloor et al., 2001; Ghafouri et al., 
2006). The BBB maintains homeostasis within the CNS by regulating the selective influx of 
substances and cells into the brain (Gloor et al., 2001; Gendelman et al., 1994; Ghafouri et al., 
2006).  
 
Figure 4: The corrosion of the BBB by HIV-1 in the brain (Ghafouri et al., 2006) 
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How HIV-1 affects oligodendrocytes and neurons is still unclear. It has been suggested that HIV-
1 can influence these cells in two ways, a direct or an indirect mechanism. The direct pathway 
refers to the release of HIV proteins directly into neuronal cells, while the indirect pathway 
involves the secretion of cytokines and neurotoxins by HIV- infected astrocytes or microglial 
cells into the surrounding intercellular space (Rappaport et al., 1999; Ghafouri et al., 2006). 
Despite the barrier property of the BBB, HIV-1 manages to enter into the brain. This occurs in 
one of four ways:  
1) the virus can infect monocytes that can migrate into the brain and subsequently differentiate 
into perivascular macrophages, 
2) the virus can infect CD4+ T cells in the periphery and the infected T cells can cross the BBB, 
3) the virus can degrade the BBB and directly enter the brain where it infects astrocytes and 
microglia, or 
4) the virus can enter by trans-cytosis of brain microvascular endothelial cells (Figure 4). 
In the brain macrophages and microglia serve as scavengers and sentinel cells, non-specifically 
eliminating foreign material and secreting trophic factors that contribute to the maintenance of 
homeostasis in the CNS (Kaul et al., 2005). However, persistent release of neurotrophins may in 
themselves lead to deleterious consequences in the brain (Rappaport et al., 1999; Kaul et al., 
2005). In general, the damaging effects of these trophic factors are mediated through the 
activation of cytokines such as TNF-β and TNF-α (Rappaport et al., 1999). In addition to these 
mechanisms, infected microglial cells may also release HIV-1 related proteins such as tat 
protein, which in turn will have toxic effects in the brain. It has been proposed that this 
mechanism may in particular have relevance to the development of HAD (Figure 5; Kaul et al., 
2001). 
Astrocytes do not have CD4 receptors and therefore it is unlikely that HIV-1 infects these cells 
directly. However, astrocytes do express other HIV-1 co-receptors such as CXCR4 and CCR5 
that may facilitate entry of the virus (Kaul et al., 2001; Ghafouri et al., 2006). Astrocytes may 
also be activated by HIV proteins (e.g. tat protein and gp120), as well as inflammatory cytokines 
such as TNF-α, IL-1β and interferon-γ (IFN-γ) (Kaul et al., 2001; Ghafouri et al., 2006). 
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Malfunction of astrocytes has been associated with significant increases in the intracellular 
calcium concentration of neurons, with concomitant dysregulation in glutamate handling. These 
neurochemical changes can result in glutamate toxicity, and the eventual death of neurons 





Figure 5: Diagram showing the release of HIV proteins and cytokines by activated microglia and 
macrophages during HIV-induced neurotoxicity (Pocernicha et al., 2005). 
 
5. The effects of HIV-1 proteins in the brain 
Studies have suggested that HAD can result from the damaging effects of viral proteins on brain 
cells. Proteins such as gp120 and tat protein have been shown to have toxic properties, while 
others (vif, vpr, vpu and nef) have been suggested to be important in establishing interactions 
between the virus and human host cells (Figure 6; Ghafouri et al., 2006; Li et al., 2009; Romani 
et al., 2010). The present study chose to focus on the effects of tat protein and therefore 




Figure 6: This figure depicts the overall genomestructure of HIV-1. The products of the various 
genes and their functions are also shown. 
Tat is a highly basic protein, non-specific and consequently has the ability to bind to many 
different RNAs (Ruben et al., 1989; Li et al., 2009). Tat protein is produced early in HIV-1 
infection, signifying its important role in regulating transcription of the viral genome especially 
via the transactivation of TAR (Tat associated region) (Campbell et al., 2005; Li et al., 2009). 
Tat protein exists either in an 86 or 101/ 104 amino acid length form (Figure 7). The tat gene 
consists of 2 exons, the first coding amino acids 1-72 and the second exon coding for amino 
acids 73-101/104 (Figure 7; Jeang et al., 1999; Li et al., 2009). The first exon of the tat gene 
codes for 5 functional regions; the first region has 1–21 amino acids and is responsible for the 
biological activity of tat protein.  
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The second region is a cysteine-rich region (amino acids 22–37). Residues 14–31 play an 
important role in viral infectiveness? (Jeang et al., 1999; Campbell et al., 2005), while the 
cysteine residue at position 31 is responsible for binding to the N-methyl-D-aspartic acid 
(NMDA) receptor on neurons. This cysteine is therefore instrumental in its neurotoxic effects (Li 
et al. 2008; 2009). Thirdly is the basic region (amino acids 49–57), and fourthly a glutamine-rich 
region (amino acids 58–72). The third and fourth regions together are responsible for binding 
and nuclear localization, and uptake of tat protein by cells (Campbell et al., 2005; Li et al., 
2009).  
The second exon of the tat gene codes for amino acids 73-101/104. This part of tat protein is 
important for transactivation, trans repression of transcription factors such as AP-1 and NF-kB, 
and virus replication (Li et al. 2008; 2009).  
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Figure 7: This figure depicts the division of tat protein into various regions. The figure also 
shows which of the two exons of the tat gene codes for the respective regions of tat protein (Li et 
al., 2009). 
6. Apoptosis 
One of the mechanisms by which HIV-1 infection may cause neurocognitive impairment is 
proposed to be via the induction of apoptosis in the brain. There are two pathways that may 




Figure 8: This illustration shows the relationship between tat protein function, the extrinsic 
pathway that mediates cell death through activation of cytokines, and the intrinsic pathway 
which involves malfunction of the mitochondrion (Pocernicha et al., 2005). 
 
Figure 9 shows how the extrinsic pathway may be initiated through activation of cell-death 
receptors such as Fas/CD95. The activation of these receptors leads to the subsequent activation 
of a number of signalling proteins that converge on the enzyme caspase-8. The function of 
caspase-8 is to cleave procaspase-3, resulting in the production of caspase-3, one of the major 
enzymes responsible for the induction of apoptosis (Li et al., 2005; Pocernicha et al., 2005; 
Romani et al., 2010).  
The intrinsic pathway starts at the level of the mitochondrion, where apoptosis-inducing 
compounds such as cytochrome c, are released resulting in the activation of caspase-9. In turn 
caspase-9 activates caspase-3 (Figure 9; Li et al., 2005; Paquette et al., 2005; Ruwanpura et al., 




Figure 9: This structure show the complex activation of neurochemical that caused the cell death 
in the brain that leads to apoptosis (Elmore, 2007) 
 
Besides the extrinsic and intrinsic pathways, stimulation of other pathways may also lead to 
apoptosis, for example those involving the activity of caspase 6. Together these pathways reflect 
the complexity of apoptosis, and the myriad of signalling pathways that participate in this mode 
of cell death (Elmore, 2007; Kantar et al., 2011). Nevertheless, it seems as if caspase-3 is 
fundamental to many pathways, and its activation is central to the final execution of the apoptotic 
process. Caspase-3 is responsible for the activation of the nuclease known as caspase-activated 
DNase (CAD) or endonuclease (ENase), whose function is to cleave DNA into 180-200 base 
pair fragments, one of the hall marks of apoptosis (Li et al., 2005; Elmore, 2007; Kanwar et al., 
2011). 
It has been proposed that tat protein may induce apoptosis by upregulating tumour necrosis 
factor-related apoptosis-induced ligand (TRAIL), and eventually activate caspase-3 (Huang et 
al., 2005). Studies showing tat protein to upregulate Fas, Fas ligand (FasL/CD95L) and TNF-α 
(Song et al., 2006) supported this proposal. Tat protein not only initiated the extrinsic pathway, 
but reports indicating its activation of the intrinsic pathway have also been documented. For 
instance, it has been suggested that tat protein interacts with the two non-polymerized subunits of 
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microtubules (α and β-tubulin dimers), as well as polymerized microtubules, and this interaction 
may lead to mitochondrial induction of apoptosis (Figure 10; Romani et al., 2010). Apparently it 
is the change in polymerization and depolymerisation microtubule stabilization that facilitates 
the release of pro-apoptotic proteins e.g. cytochrome c, to induce the intrinsic pathway 
(Campbell et al., 2004; Romani et al., 2010).  
 
 
Figure 10: A diagram showing the induction of apoptosis by tat protein altering the microtubule 
structure within a cell. This disturbance in cytoskeletal stability leads to the activation of the 
intrinsic pathway of apoptosis (Romani et al., 2010). 
 
7. Other mechanisms of tat-mediated cell death 
It has been shown that tat protein alters calcium homeostasis within neurons by interfering with 
calcium regulating systems in the plasma membrane and endoplasmic reticulum (Haughey and 
Mattson, 2002; Sharma and Bhattacharya, 2009). Abnormal increases in intracellular 
concentrations of calcium allow this ion to bind to calmodulin, leading to the activation of a 
number of signalling cascades, resulting in the inappropriate production of cAMP, or activation 
of nitric oxide synthase and protein kinase C. Previous studies have linked these compounds to 
cell death (Lipton, 2004; Li et al., 2005; Cross et al., 2011).  
In addition a recent study by Gupta et al. (2010), has demonstrated that tat protein may also 
cause neuronal damage by disrupting glutamate homeostasis in the brain. Glutamate is the major 
excitatory neurotransmitter in the central nervous system (Lipton, 2004), and has been associated 
with neuronal cell death primarily due to its excessive activation of N-methyl-D-aspartate 
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(NMDA)-type glutamate receptors. Overstimulation of these receptors results in extreme Ca
2+
 
influx through this ion channel (Lipton, 2004; Cross et al., 2011).  
Alternatively, tat-mediated glutamate excitoxicity may stem from the interaction of tat protein 
with glutamate transporters located on glial cells. To prevent excitotoxicity, the proper 
functioning of Na
+
-dependent glutamate transporters, or extracellular excitatory amino acid 
transporters (EAAT-1 and EAAT-2) on astrocytes, and EAAT-3 on neurones is important for 
maintaining a low concentration of glutamate in the brain (Figure 11; Chrétien et al., 2002; Cross 
et al., 2011). Tat protein has been shown to specifically derail the normal functioning of the 
cystine/glutamate antiporter  through the activation of stress-related signalling pathways such as 
p38 and p42/44 (ERK) (Gupta et al., 2010).  
Also, during HIV replication, the virus consumes substantial amounts of cysteine, thereby 
increasing the activity of the antiporter and subsequently increasing glutamate release into the 
extracellular space (Cross et al., 2011). Simultaneously, the shortage of available cysteine 
disturbs glutathione synthesis leading to glutathione depletion and the eventual accumulation of 
pro-oxidative substances. These oxidants in turn impair the function of other EAATs, blocking 
extracellular glutamate uptake and consequently promote glutamate-mediated excitotoxicity 
(Figure 11). It is interesting to note that the presence of oxidative stress has been observed in the 





Figure 11: A diagram illustrating the involvement of glutamate transporters in the regulation of 
the extracellular concentration of glutamate in the brain. The diagram also indicates possible 
areas of interference in glutamate homeostasis during HIV replication (Cross et al., 2011). 
 
8. Models to study cognitive function in rodents 
The hippocampus is one of the limbic structures of the brain that plays a prominent role in 
cognitive processes such as learning, memory storage and spatial navigation. Not surprisingly it 
is also the brain area that is first to show damage in people suffering from cognitive impairments 
(Colombo and Broadbent, 2000). Because of its devastating effects on the quality of life, rodent 
models have been developed to study the pathophysiology of disorders associated with 
abnormalities in learning and memory. Rodent models can reflect HIV-1 pathogenesis and are 
also helpful in testing the therapeutic measures or vaccination of HIV (Gorantla et Al., 2012). As 
much as HIV-1 does not infect rodent cells, mice and rat models can be used to mimic the viral 
infection by using transgenic rodents to express viral genes, or by transplanting HIV-1 infected 
cells into immunodeficient rodent tissues (Gorantla et Al., 2012). 
In experiments focusing on HIV-associated cognitive impairments, animal models have been 
created by injecting HIV-infected monocytes into the basal ganglia or hippocampus of the 
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animal (Wang et al., 1999; Zink et al., 1999; Li et al., 2009). After the intracranial injections the 
changes in cognitive behavior of the animal was assessed with the use of 2 apparatuses that have 
been designed to measure learning and memory in rodents. These are the Morris water maze test 
and the light/dark box test.  
8.1. The Morris water maze test 
This test assesses the exploratory and spatial memory of rodents (Morris, 1981). The maze 
consists of a circular pool, 1m in diameter, in which a hidden platform is located in one of the 
imaginary quadrants. The water is usually opaque so that the platform is not easily visible in the 
water. Also, the temperature of the water is kept between 22-25°C so that the animal is not 
exposed to hypothermic stress, once it’s placed in the water. 
The test entails 3 training sessions, usually on 3 consecutive days, with a test trial on the 4
th
 day 
following the last training session. During the training sessions the animal is allowed to explore 
the water maze in order to find the hidden platform. The animal is given a maximum of 120s for 
this challenge. Failing to find the platform, the animal is guided to it, permitted to stay at least 
10s on the platform to familiarise it with the position of the platform within the maze. For each 
of the subsequent training sessions, the animal is place in a different starting quadrant. To do the 
test the rodent is placed in any quadrant other than where the hidden platform is located, with the 
animal facing the wall of the water maze.  
The parameter recorded is the time taken for the rat to reach the hidden platform. Control 
animals usually learn the position of the hidden platform quickly, and hence the time period 
required to locate the hidden platform decreases progressively with each training session. On the 
other hand, cognitively impaired animals struggle to learn the position of the hidden platform, 




Figure 12: This diagram shows the dimensions of the Morris water maze (Morris, 1981) 
 
8.2. The Light/Dark Box 
This test was designed by Boizot in 1985 to primarily assess the spatial memory and navigation 
skills of rodents. During this test the animals learn a path that leads them from the fearful light 
compartment of the light/dark box, to the more preferred dark compartment. During the testing 
phase, the learned path is made more complex by the insertion of obstacles. The obstacles 
consisted of adding compartment dividers with different positions of holes at the bottom. While 
the initial divider has a hole in the center, the position of the holes in these extra dividers is 
towards the left and right corners respectively. This arrangement increased the difficulty of the 
new pathway for the animal to find its way to the dark compartment. The ability of the animal to 
navigate its way i.e. time taken to reach the dark compartment, is then documented. Control rats 
have no difficulty in achieving this goal, while impaired animals either do not find their way or 
use a much longer time to reach the dark compartment. 
 
Figure 13: A picture of the light/box test with its two different compartments (Boizot, 1985) 
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9. Aim of the present study 
The overall aim of the present study was to develop a rodent model that displayed aspects of 
HIV-associated cognitive impairment. We then wanted to use this model to investigate whether 
picolinic acid could be considered as an adjunct treatment to assist in reversing the neuronal 
damage accompanying HIV infection. Briefly our approach was to 
 inject tat protein directly into the hippocampus of rats using stereotaxic techniques; 
 identify any cognitive behavioral change that may occur following the tat protein 
injection, using the Morris water maze and the light/dark box tests; 
 assess the extent of apoptotic cell death in the hippocampus induced by the injection of 
tat protein; and 


























1. Experimental design  
 
The overall objective of the present study was to inject tat protein into the hippocampus of rats to 
induce cognitive impairment comparable to HIV-associated dementia, and to investigate the 
ability of picolinic acid to normalize tat protein-induced changes in brain function.  
In order to achieve this objective a total of 32 rats were randomly divided into four groups 
namely, 
(1) a control group that was treated with 3ml of saline intraperitoneally prior to receiving a 
bilateral injection of 100μl of tat buffer solution into the dorsal hippocampus (n=8);  
(2) a group that was treated with saline but received a bilateral injection of 5μg of tat protein 
dissolved in a volume of  100μl tat buffer solution, intrahippocampally (n=8);  
(3) a group that received an intraperitoneal injection of picolinic acid 10mg/kg before being 
treated with tat protein (n=8), and  
(4) a group that were treated with picolinic acid before receiving bilateral injections of tat buffer 
solution in their dorsal hippocampi (n=8). 
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The following day (24hours later), all animals were subjected to behavioral tests (the light/dark 
box and Morris water maze tests) to assess their learning and memory abilities. The animals were 
decapitated 8 days after the intrahippocampal injections, their hippocampi dissected and snap 
frozen in liquid nitrogen and stored at -80ºC. These tissues were later subjected to further 
neurochemical analysis that included flow cytometry, real time PCR and Western blotting. 
Ethical approval for all experimental procedures was obtained from the Animal Ethics Sub-




Male Sprague-Dawley rats (250-300g) were used in this study. Animals were provided by and 
housed in the Biomedical Research Center of the university, and were kept under laboratory 
conditions that included a room temperature of 25ºC and humidity of 70%. The day/night cycle 
was changed to lights on at 11am/lights off at 11pm in order to perform the behavioral test 
during the dark period of the cycle when the animals are naturally more active. The animals had 
free access to food and water.  
 
2.2.Materials 
Tat protein was produced by one of our colleagues as previously described (Ramautar et al., 
2012). The tat protein was expressed in BL21 E. coli B cells, and subsequently isolated and 
purified by ion exchange and affinity chromatographic techniques. Tat protein was injected 
bilaterally into the hippocampus of animals at a concentration of 1μg/20μl. A volume of 100μl 
was injected into each hemisphere of the rat. Picolinic acid was obtained from (Sigma-Aldrich, 
St Louis, USA) and administered at a concentration of 3.36mg/3ml i.e. a dose of 10mg/kg 
intraperitoneally to the animals. All other general drugs and chemicals were obtained from 
Sigma-Aldrich (St. Louis, USA). The source of specialised chemicals for the various 








3.1. Surgical technique 
A stereotaxic procedure was adopted to inject the tat protein into the dorsal hippocampus. 
Briefly, animals were anaesthetized with a combination treatment of pentobarbital (60mg/kg, 
i.p), followed by atropine sulfate (0.3mg/kg, i.p.). After full anaesthesia has been reached, the 
skin above the head was shaved and disinfected. The head of the rat was positioned in a David 
Kopf
®
 stereotaxic apparatus. This was followed by an incision in skin covering the skull. 
Subcutaneous tissue was removed and the position for the sites of injection clearly marked on the 
skull. These were at the following coordinates: Anterior-Posterior (AP) = −3.7mm posterior to 
bregma, Medio-Lateral (ML) = ±2.6mm left or right to the midline, and Dorsal-Ventral (DV) = -
3.2mm from the surface of the skull. After the piercing of the dura mater, a Hamilton Syringe 
was used to infuse the tat protein into the CA1-2 region of the dorsal hippocampus. A total 
volume of tat (100µl) was carefully dispensed into the brain over a period of 15 minutes. 
After the infusion period a further 3 minutes elapsed before the needle was slowly retracted from 
the brain. This additional time period was allowed to facilitate maximum diffusion of the Tat 
protein into the hippocampal tissue. Once the needle was completely withdrawn, the skin was 
sutured. Animals were then returned to their home cages for recovery. Control animals were 
subjected to the same procedure, but received 100µl of Tat buffer solution.  
Tat protein sticks to the wall of glass. This necessitated the Hamilton syringe first to be pre-
treated according to methods described previously (Wang et al., 1999; Maragos et al., 2003). 
Briefly the Hamilton syringe was pre-treated with a solution of dimethyldichlorosilane and then 
sequentially rinsed with deionized water, absolute alcohol and again with deionized water. It was 
then dried in a 60 °C oven for at least 1hour and then cooled to room temperature. The syringe 
was then ready for experimental use. 
 
3.2. Behavioral Tests 
The animals were subjected to two behavioral tests to assess the deficits in cognition namely the 
light/dark box test and the Morris water maze. These tests determine the learning and recall 
ability of rats, and cover exploratory, navigation, spatial and contextual memory. Abnormalities 
in these aspects of memory in the rat have been suggested to reflect some of the neurocognitive 
symptoms of the HIV patient such as poor concentration, slowness in thinking, difficult in 
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remembering or ability to learn (impaired registering, recall and recognition of previous 
information). A more detailed description and explanation of these tests have been provided in 
Section 8 of Chapter 1 - the Literature Review. 
 
3.3. Gene expression (Real-Time PCR) 
Total ribonucleic acid (RNA) was isolated from previously stored snap frozen hippocampal 
tissue. The hippocampal tissue weighing between 20-50mg was homogenized in 175µl of 
QIAzollysis buffer (Qiagen, Bio-Rad, SA) using a sonicater (12000 Hz for 10 seconds). The 
RNA was extracted as per manufacturer’s instructions. In-depth details of the procedure 
areattached as Addendum A.  The purity of the RNA was determined using a Nano-drop® ND-
100 Spectrophotometer (Thermo Scientific, SA) with the purity of RNA taken at the absorbance 
ratio of A260/A280. RNA was considered as pure if the absorbance ratio ranged between 1.7 and 
2.5.  
The isolated RNA was used to synthesize cDNA using the iScrip™ cDNA Synthesis Kit (Bio-
RAD, SA), as per manufacturer’s instruction. The RNA was converted to cDNA using the Gene-
Amp 9700 Thermocycler (Applied Biosystems, California, USA), with the following parameters: 
melting point 25°C for 5 minutes, 40°C for 30 minutes, 85°C for 5 minutes and hold at 4°C.  The 
cDNA was then stored at –20 °C until further analysis (Addendum B) 
The primers used were designed and produced commercially (Inqaba, SA) and their sequence is 
shown in Table 4. The expression of caspase 3 gene was subsequently assessed using a light 
cycler (Roche Diagnostics). The Light Cycler-master mix consisted of the following: 5.4µl 
water, 1.6µl MgCl2 (3 mM), 1.0µl forward primer (1.0 µM), 1.0µl reverse primer (1.0 µM) and 
1.0µl Fast Start SYBR Green I; (Roche Diagnostics, SA) and 1.0µl cDNA. RNA was quantified 
using the Light Cycler under the following PCR conditions: one cycle consisting of 95 °C for 10 
minutes followed by 45 cycles of 95°C for 15 seconds, 60°C for 1 minute and 72°C for 10 
seconds with a single fluorescence measurement (Mackraj et al., 2008; Zhen-Hong et al., 2011). 
This was followed by a final cooling step to 40°C. A dilution series of CASP-3 gene and 
GAPDH amplicons were used to construct a standard curve. Quantitative analysis of the data 
was analyzed using Light Cycler software 4.1 (Roche Diagnostics). Melting curve analysis was 




Table 4. Sequences of primers for real-time qPCR (Inqaba, SA) 
Target gene Primers (5′-3′) (nt) PP bp 
Caspase-3    F5′-
GGTGCCACTATGAATTTGAAATTAC-3′ 
25 1216-1240 25 
R5′-CCAACTCTTCATTTCCACAG-3′ 20 1401-1382 20 
 
3.4. Western Blot 
The hippocampal tissue of 4 animals per group was homogenized in 600µl of RIPA buffer 
(8.76g NaCl, 10ml Tris pH 7.2 (1M Tris), 10ml 10% SDS, 1ml Triton X100, 10g Na-
deoxycholate and 10ml of 0.5M EDTA). The protein lysate was stored at -80°C. The protein 
concentration was quantified using the Bradford method reagent (50 mg Coomassie Brilliant 
Blue G250, 50 ml methanol, 100 ml 85% Phosphoric acid and 850 ml distilled water). Samples 
were diluted in a ratio of 1:2 with a sample buffer (3.55ml distilled water, 1.25ml 0.5 Tris-HCl 
pH 6.8, 2.5ml glycerol, 2ml 10% SDS and 0.2ml 0.5% Bromophenol blue), 50µl of β-
mercaptoethanol was added and heated to 95°C for 4minutes.  
The electrophoresis apparatus was set up and filled with 1x running buffer (30.3 g Tris base, 
144g glycine and 10g SDS). The protein samples were loaded up to 25µl (20 µg) protein in each 
well. (Note: The volume of protein samples varied to adjust to similar protein concentrations 
being loaded). The samples were run on the SDS-PAGE gel at 200V (400 mA) for about 45 to 
50 minutes or until the bottom most marker band reached the bottom of the gel. Proteins 
separated on the gels were then transferred to nitrocellulose membranes using the Turbo blot 
apparatus (Bio-Rad, SA). Transfer required 30 minutes with this method. The membranes were 
subsequently blocked in non-fat milk (5g fat free milk powder in 100 ml TBS-T), for 2 hours. 
Membranes were then incubated overnight with the caspase 3 primary antibody in TBS-T 
(1:1000, Cell Signaling Technology, USA)after which they were washed three times with TBS-
Tween. The membranes were then incubated with anti-rabbit IgG HRP-linked antibody that 
served as the secondary antibody (1:1000, Cell Signaling Technology, USA) for 2 hours and 
wash two times with TBS-Tween and again with plain TBS. The chemiluminescence peroxidase 
substrate-3 reagents were added to the membranes and these were finally viewed on a Chemi-doc 
system (Bio-Rad, SA). 
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3.5. Flow Cytometry 
3.5.1. Tissue preparation protocol for flow cytometry: 
For flow cytometric analyses, hippocampal tissue had to be converted into a cell suspension. The 
frozen hippocampal tissue was cut into 2mm pieces, placed on the grid part of a Medicon tube 
and 1ml of PBS was added to the tissue. The Medicon tube was then placed into the Medi-
machine (Becton Dickinson, SA) and the tissue homogenized for 30 seconds. 1ml of homogenate 
was drawn from the Medicon tube using a clean syringe. 
The homogenate was filtered through Falcon filters into Falcon tubes and centrifuged for 10 
minutes at 4500 r.p.m. The supernatant was discarded and the palette suspended in 1ml of PBS. 
A cell count was done using a standard Nieubauer haemocytometer. This was necessary to 
ensure that at least 1x10
6
 cells were present in each sample tube for analysis. 
3.5.2.  Preparation of sample for flow cytometric analysis 
The 1x10
6
 cell suspension was again centrifuged for 10 minutes at 4500r.p.m and the resulting 
supernatant discarded. The pellet was now resuspended in 0.5ml of cytofix/cytoperm solution 
(Becton Dickinson, SA) and incubatedon ice for 20minutes. After this the resuspended cells were 
washed with 0.5ml of Perm/wash (Becton Dickinson, SA). This step was repeated. The cells 
were then incubated with polyclonal rabbit anti-active caspase-3 antibody (Caspase 3 kit, The 
Scientific Group, SA) in the dark for 30-50 minute at room temperature. The cell suspension was 
then centrifuged (10 minutes at 4500 r.p.m.), washed with 1ml of BD Perm /wash, and finally 
resuspended in 0.5ml of BD Perm/wash for analysis on a FACS Calibur flow cytometric 
machine (Becton Dickinson, SA). Details of the PE Active Caspase-3 Apoptosis Kit can be 
found in Addendum C. 
 
4. Statistics  
All results are presented as mean ±SEM. The data was analyzed using the software program 
Graph Pad Prism (version 5, San Diego, California, USA). Data was subjected to either ANOVA 
with repeated measures or ANOVA where appropriate. This was followed by Tukey’s multiple 







3.1. Behavioral test (Light/dark box) 
Animals were subjected to three days of learning trials and a test trial was performed on the 4
th
 
day. The group that was injected with tat buffer showed good learning and memory ability when 
these animals were tested in the light/dark box (Figure 14). Already on the second trial day the 
time to move into the dark compartment was significantly reduced when compared to trial day 1 
(56.8 ± 2.5 vs 17.5 ± 5.9; p < 0.05). This significant decrease in time to find the dark 
compartment prevailed on trial day 3, as well on the test day (Figure 14; trail 3 = 7.1 ± 1.4; Test 
= 12.9 ± 2.0; p < 0.05). 
Unlike the tat buffer-treated animals, the group that received tat protein showed poor learning 
and memory ability (Figure 14). While there was a decrease in time taken to enter the dark 
compartment between trial 1 and 2 (56.25 ±2.498vs43.38 ± 5.982, p > 0.05), this change was not 
significant. Similarly, a further reduction in time on trial day 3 (37.75 ± 8.845; p > 0.05) still did 
not reach significance when compared to either trial day 1 or 2. When the animals were tested on 
day 4, they required a comparable amount of time to enter the dark compartment as trial day 2 
and 3. There were therefore no significant differences in the time taken for the animals that were 
treated with tat protein to enter the dark compartment when assessed on the respective days 


















Figure 14: This graph represents the time spent by tat buffer (control) and tat protein treated 
animals to move from the light compartment into the dark compartment of a light/dark box. 
Values are the mean ± SEM of 8 animals. 
*p<0.05, significantly different from trial 1 (ANOVA with repeated measures followed by 
Tukey’s multiple comparison test). 
 
3.2. Morris water maze test 
This test assesses explorative and spatial learning and memory. The group that was injected with 
tat buffer showed good learning and memory capability when tested in the Morris water maze. 
The time spent by these animals to find the hidden platform during trial 2 was significantly 
reduced when compared to trail 1 (Figure 15; trial 2 = 94.63 ± 12.59vs trial 1 30.88 ± 7.222; p < 
0.05). This significant decrease in time spent to find the hidden platform was again observed 
during trail 3, as well as during the test trial on day 4 (Figure 15; trial 319.13 ± 7.376; test = 
23.88 ± 4.223; p < 0.05). 
In contrast, rats that were treated with tat protein demonstrated poor learning and memory 
ability. The differences in time spent to find the hidden platform between the various trails as 
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well as the test trial were not significant (Figure 15; trial 1 = 87.63 ± 13.91; trial 2 = 100.3 ± 
13.90; trial 3 = 60.00 ± 15.63; test = 76.50 ± 14.05; p >0.05).  
Tat protein treated rats that also received picolinic acid showed a partial recovery in their 
learning and memory ability when tested on the Morris water maze (Figure 16). While there 
were no significant differences between the times spent to find the hidden platform during the 3 
learning trials, a significant change was observed between the times spent to find the hidden 
platform during trial 2 versus the test trial. (Figure 16; trial 2 = 87.80 ± 11.99vs test =32.00 ± 










Figure 15: This graph represents the time spent by tat buffer (control) and tat protein treated 
animals to find the hidden platform during a 3-day trial / next-day test session in a Morris water 
maze. The values are the mean ± SEM of 8 animals. 
*p<0.05, significantly different from trial 1 (ANOVA with repeated measures followed by 
Tukey’s multiple comparison test). 
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Figure 16: This graph represents the time spent by animals that were treated with tat protein plus 
picolinic acid during a 3-day trial / next-day test session in a Morris water maze. The values are 
the mean ± SEM of 5 animals. 
*p<0.05, significantly different from trial 2 (ANOVA with repeated measures followed by 
Tukey’s multiple comparison test). 
 
Previous studies from our own laboratory (Ramautar et al., 2012) and others (Li et al., 2005; 
Paquette et al., 2005; Ruwanpura et al., 2008; Romani et al., 2010) have shown that tat protein 
may result in apoptotic cell death. In our study we subsequently focused on caspase 3 activity 
and expression levels, since it is one of the executioner enzymes central to apoptosis. 
 
3.3. Real-time PCR   
Real-time PCR was used to determine the effects of tat protein on the transcription levels of the 
caspase 3 gene in the hippocampus. Our data showed that injection of tat protein led to a 
significant increase in caspase 3 mRNA levels when compared to the tat buffer treated control 
group (Figure 17). This increase was not seen in the tat protein group treated with picolinic acid 
that showed caspase 3 mRNA levels similar to control animals (Figure 17).  

























































Figure 17: This graph represents the expression of mRNA of caspase 3 gene in the hippocampus 
of rats treated with tat buffer, tat protein, picolinic acid alone or tat protein and picolinic acid. 
Values are the mean ± SEM of 3 animals. The experiment was done twice.  
*p<0.05, significantly different from control, picolinic acid and tat+picolinic acid groups 
(ANOVA followed by Tukey’s multiple comparison test). 
 
3.4. Western blot 
Western blot analysis was used to correlate our real time PCR results, i.e. mRNA transcription 
levels, with protein expression levels. Here visual inspection of the Western blot showed that tat 
protein stimulated both pro-active and active caspase 3 expression levels (Figure 18).  Treatment 
with picolinic acid prevented this increase, especially in the case of active caspase 3, where its 
expression was significantly reduced (Figure 18). Statistical analysis of the intensity bands 
showed that the increase in active caspase 3 expressions was significantly reduced by picolinic 






Figure 18: A representative Western blot of 3 experiments showing pro-caspase 3 and active 
caspase 3 staining in tat buffer treated, tat protein treated, tat buffer plus picolinic acid treated 
and tat protein plus picolinic acid treated animals.  
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Figure 19: A graph showing the mean intensities of 3 Western blots of the pro-active caspase 3 
and active caspase 3 bands of the various treated groups. 
*p<0.05, significantly different from tat protein treated group (ANOVA followed by Tukey’s 
multiple comparison test). 
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3.5. Flow cytometry 
Flow cytometric techniques were used to assess intracellular expression of caspase 3 in the cells 
of the hippocampus. Figure 20 suggested the tat protein treated group to show higher caspase 3 
staining than the group that was treated with tat buffer, while the group of rats treated with tat 
buffer plus picolinic acid showed an even greater intensity of staining. However, statistical 
analysis of the means of the results of 3 animals showed that these increases were not 
significantly different (Figure 21). 
a)                   b)  
c)                   d)   
Figure 20: Representative flow cytometry scatter graphs of one animal showing the level of 
caspase 3 active cells, a) Tat buffer group; b) Tat protein treated group, c) Tat buffer plus 
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Figure 21: This graph represents the caspase 3 staining in hippocampal cells obtained from tat 
buffer treated, tat protein treated, tat buffer plus picolinic acid treated and tat protein plus 
















Recent studies showed that more than 60% of HIV-infected individuals go on to develop HIV 
associated neurocognitive disorder (HAND) (Bansal et al., 2000; Grant, 2008; Singh et al., 
2010). This alarming statistic has been a primary driver for current studies to continue their 
search for elucidating the mechanism by which the virus causes this disorder. In the present 
study we tested the hypothesis that the viral protein, tat, could lead to neuronal cell death, 
thereby leading to the development of cognitive disabilities. In doing so, we injected tat protein 
into the hippocampus of rats and assessed the effects thereof on the learning and memory ability 
of the animal. Simultaneously, we examined whether picolinic acid could block the deleterious 
effects of tat protein. Our study specifically investigated apoptotic cell death and particularly 
focused on the expression of the executioner enzyme caspase 3.  
In brief our findings were:  
1. Injection of tat buffer into the hippocampus has no effect on learning and memory, 
2. Injection of tat protein into the hippocampus impaired learning and memory, 
3. Tat protein-treated animals showed upregulation of the caspase 3 gene as exhibited by 
PCR, 
4. Western blot analysis showed increased expression of caspase 3 enzyme in the tat 
protein-treated group, 
5. Assessment of the level of apoptotic death by flow cytometry provided differences 
between the various groups of animals, but these were not significant, and 
6. Pre-treatment with picolinic acid significantly prevented the deleterious effects of tat 
protein. 
HIV-tat protein is a trans-activator protein that has previously been implicated in the 
development of neurocognitive impairment (Li et al., 2009; Carey et al., 2012). In our study, 
injection of tat protein into the hippocampus also led to difficulties in learning and memory as 
assessed by two paradigms, namely the Morris water maze and light/dark box. The Morris water 
maze is the most popular test that is used to determine hippocampal-dependent spatial-based 
learning and memory function in rodents (Self et al., 2009; Fitting et al., 2013). For example, 
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Self et al. (2009) employed the Morris water maze to assess the behavioral changes in animals 
that were exposed to binge-like alcohol consumption prior to tat protein treatment. In these 
experiments the authors showed that rats that received alcohol and tat protein performed 
significantly poorer in the Morris water maze compared to all other experimental groups. 
Likewise, Fitting et al. (2013) demonstrated how increased expression of tat protein in transgenic 
mice caused a suppression of long term potentiation in Schaffer collateral - CA1 pyramidal cell 
synapses, and this suppression was associated with deficits in learning and memory. Similar to 
these previous studies, our results also indicated a decline in learning and memory in the Morris 
water maze in those rats that were treated with tat protein. 
The finding of tat-mediated cognitive impairment as observed in the Morris water maze, was 
confirmed by data obtained from the light/dark box experiments. The light/dark box is used to 
test anxiety-like behavior and the explorative or navigation skill movement from the light 
compartment to the dark compartment (Boutin and Hoscoёt, 2003). The fact that tat protein-treat 
animals required a significantly longer time to reach the dark compartment than the tat buffer 
controls supported the notion of tat protein disrupting normal learning and memory processes in 
these animals. 
It is well known that the hippocampus is one of the important parts of the brain that is 
responsible for learning and memory. Thus, the negative effects of tat protein on cognitive 
function can be attributed to the protein having direct toxic effects on hippocampal neurons. In 
the present study the injection of tat protein directly into the hippocampus was toxic to the cells 
as suggested by increased caspase 3 transcription and expression, an enzyme closely associated 
with apoptotic cell death (Elmore, 2007). Our results are in agreement with those of others also 
reporting neurotoxic effects of tat protein on hippocampal cells followed by learning and 
memory impairment (Li et al., 2009; Carey et al., 2012). These authors used genetically 
engineered mice to achieve an increase in the expression of tat protein in the hippocampus, and 
demonstrated that this elevation in tat levels could cause abnormalities in cognitive behavior. 
Additional evidence for tat protein-induced toxicity stems from both in vitro and in vivo 
experiments. Exposing hippocampal slices to tat protein resulted in pyramidal cell loss in the 
CA3 region that was accompanied by a concomitant decrease in microtubule associated protein-2 
staining (Magaros et al., 2003). This result correlated well with the reduction in microtubule 
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associated protein-2 staining that these authors observed in the hippocampal tissue from patients 
suffering from HIV encephalitis (Magaros et al., 2003). 
Since caspase 3 expression was raised in the hippocampus of tat protein-treated rats, it is likely 
that damage to hippocampal cells in our experiments was mostly due to apoptosis. This result is 
plausible as in vitro studies have shown tat protein to induce caspase 3 driven apoptosis in CEM-
GFP cells (Ramautar et al., 2012), as well as human enterocytes (Buccigrossi et al., 2011). 
Furthermore, a recent study by Gibellini et al. (2012) has shown that tat protein may induce the 
expression of different cytokines such asIL-1, IL-6, M-CSF, IL-10, TNF-α, and RANKL that 
affect neuronal cells negatively. It is well known that some of these cytokines are initiators of 
apoptotic pathways (Sei et al., 1995; Nagata, 1996). 
Apoptosis can occur at least via two pathways, namely the extrinsic or the intrinsic pathway. The 
extrinsic pathway causes cell death through the upregulation of cytokines, chemokines and 
death-inducing receptors (e.g. FAS/CD95 receptor). Cell death via the intrinsic pathway involves 
the release of apoptosis-inducing molecules such as cytochrome c from the mitochondrion, 
followed by the activation of APAF-1 and the executioner enzymes caspases 9 and caspase 3 (Li 
et al., 2005; Paquette et al., 2005; Ruwanpura et al., 2008; Romani et al., 2010). These enzymes 
are responsible for the cleavage of DNA, the formation of apoptotic bodies and eventually cell 
death. 
Apoptotic cell death is not the only strategy that tat protein could have used to induce cell death. 
For instance, tat protein may cause abnormal increases in intracellular concentrations of calcium, 
facilitating this ion to bind to calmodulin with subsequent activation of a number of signalling 
cascades. As such, inappropriate levels of cAMP are produced or there may be undesired 
activation of nitric oxide synthase and protein kinase C enzymes, leading to cell death (Lipton, 
2004; Li et al., 2005; Cross et al., 2011). In addition, tat protein has been shown to increase 
oxidative stress (Pocernich et al., 2005). Reactive oxygen species are toxic oxygen moieties, 
such as hydroxyl radical, peroxyl radical, superoxide anion, hydrogen peroxide, and 
peroxynitrite, and all of them have been associated with the oxidation of proteins and DNA, and 
the peroxidation of lipids. Oxidative stress can also induce the production of ceramide, 
sphingomyelin and4-hydroxynonenal. High levels of these compounds have been found in the 




Pre-treating animals with picolinic acid prior to tat protein administration blocked the 
detrimental effects of tat protein with respect to learning and memory behavior, and the 
transcription and expression of caspase 3. This result was in line with an earlier in vitro study 
where PA was shown to inhibit transactivation and apoptosis in CEM-GFP cells (Ramautar et 
al., 2012).  
Picolinic acid occurs naturally in the body albeit in small concentrations. It is a by-product of the 
kynurenine pathway where tryptophan is converted to quinolinic acid (Grant et al., 2009). 
Picolinic acid can be found in primary neurons and astrocytes. It is also present in CSF at low 
concentrations. Picolinic acid is a metal chelator and can bind cations such as zinc, manganese, 
copper and iron (Grant et al., 2009).  
One of the main functional components of tat protein is its zinc-finger moiety that is responsible 
for transactivation of virus and cellular genes (Davies et al., 2010; Ramautar et al., 2012). Amino 
acids 1-72 of the tat protein form five regions that are responsible for the biological activity of tat 
protein. These amino acids are coded by the first exon of the tat protein gene. The two regions 
that are rich in cysteine residues form the binding sites for zinc (Campbell and Loret, 2009).  
Since picolinic acid is a potent metal chelator, one of the mechanisms by which it can inhibit the 
action of tat protein, is to sequester its zinc ions. In vitro studies have attributed the prevention of 
tat protein-induced apoptosis in CEM-GFP cells to the ability of picolinic acid to competitively 
remove zinc from the zinc-moieties in tat protein (Ramautar et al., 2012). This explanation is 
plausible as other specific metal chelators have also been used to inhibit HIV transcription 
(Debebe et al., 2007). These authors demonstrated how iron, a clinically approved oral iron 
chelator blocked HIV-1 transcription by decreasing the expression of cyclin-dependent kinase 2, 
a regulator of the cell cycle that is essential for tat-dependent transcription (Debebe et al., 2007).  
Alternatively picolinic acid could also have interfered with the neurotoxic effects of tat protein in 
other biological areas. For example, picolinic acid could have acted as an anti-oxidant, stabilized 
blood brain barrier permeability or could have limited the production of inflammatory cytokines 
as picolinic acid does cross the BBB. All these are mechanisms by which tat protein could have 
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induced its toxic effects (Jones et al., 1998; Banks et al., 2005; Campbell and Loret, 2009). 
























Neurocognitive impairment in persons living with HIV has become the new concern in the fight 
against the HIV/AIDS pandemic, especially in lieu of the significant improvement in longevity 
brought about by antiretroviral treatment. In spite of the high prevalence rates of HIV associated 
neurocognitive disorders (HAND) its pathophysiology remains poorly understood and 
consequently the effective management thereof is also lacking. The present study was 
subsequently conducted to improve our current understanding of HAND and to investigate the 
potential of picolinic acid as an adjunct therapy for HAND. 
The broad objectives of our study were therefore: 
 To establish a rat model that displayed partial symptoms of HIV-associated 
neurocognitive disorder; 
 To identify a molecular mechanism that may explain these symptoms; and  
 To evaluate the potential of picolinic acid to be considered as an adjunct treatment in the 
management of HIV-associated neurocognitive disorders.  
 
To achieve the first objective, bilateral injections of tat protein were made directly in the 
hippocampus of Sprague-Dawley rats. The cognitive behavior of these animals was assessed by 
testing their learning and memory ability in a Morris water maze and Light/Dark box. Our results 
showed that tat protein treated rats performed worse than their tat buffer treated controls, 
suggesting that learning and memory function was impaired in those animals that received tat 
protein.  
We investigated whether the deleterious effects of tat protein on learning and memory could 
have been due to apoptotic cell death in the hippocampus. We focused on caspase 3 as our 
indicator of apoptosis. This was done by assessing caspase 3 gene transcription using PCR 
techniques, determining its expression with Western blots and measuring enzyme staining 
activity on a flow cytometer. These experiments led us to believe that tat protein may induce 




Pretreating rats with picolinic acid significantly decreased the damaging effects of tat protein 
with respect to cognitive behavior as well as caspase 3 activity. This result therefore suggested 
that picolinic acid may be considered as a therapeutic agent in the management of HAND. 
Further studies however, will be necessary to characterize its toxicological profile and 
pharmacokinetic properties. 
A number of limitations of our study have been identified. Larger group sizes would have 
allowed us to increase the statistical power of experiments that could have led to more clear 
recommendations. At present we remain cautious about our findings. We also experienced 
difficulty in preparing a homogenous cell suspension for the flow cytometer experiments, and 
cellular damage during this preparation process could have clouded our data, resulting in less 
convincing observations. Another shortfall of our study was that we did not ascertain whether the 
toxic effects of tat protein were limited to neurons, glial cells or both. This however, may be the 
basis for a future study. 
Additional studies that are considered for the future include investigating how 
 exposure to stress would influence the toxic effects of tat protein, 
 tat protein alters glutamate homeostasis in the hippocampus, 
 neurotrophins in the hippocampus respond to tat protein toxicity, and  
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